PARP inhibitors have had great success in treating a number of cancers but the German major has placed a $65m bet that Nerviano's selective PARP1 approach could produce a safer and more efficacious option.
Merck KGaA is hoping to position itself as a leader among companies looking to develop next-generation PARP inhibitors by teaming up with Italy's Nerviano Medical Sciences.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.
The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.
Adstiladrin sales hit €70m in first full year on the market
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
Adstiladrin sales hit €70m in first full year on the market
ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.
The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.
